Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action

British Journal of Cancer

Volumn 90, Issue , 2004, Pages S2-S6

  Osborne, C K ^a   Wakeling, A ^b   Nicholson, R I ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Advanced breast cancer; Faslodex; Fulvestrant; Mechanism of action; Oestrogen receptor antagonist

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; BREAST TUMOR; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CROSS RESISTANCE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; ESTROGEN ACTIVITY; FLUID RETENTION; GENE EXPRESSION; HEART DISEASE; HUMAN; NAUSEA; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS;

EID: 1842684035     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601629     Document Type: Article

References (54)

1. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
2. The search for the ideal SERM
3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial
4. Gene regulation by steroid hormones
5. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen
6. Endocrine therapy in the treatment of metastatic breast cancer
7. Buzdar AU (2003) Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 9: 468S-472S
8. Sequencing of endocrine therapies in breast cancer - integration of recent data. Clin Cancer Res 9: 468S-472S
9. The antiestrogen ICI 182780. Disrupts estrogen receptor nucleocytoplasmic shuttling. Clin Cancer Res 9: 468S-472S
10. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE (1994) Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408-414.
11. Dos Santos EG, Dieudonne MN, Pecquery R, Le Moal V, Giudicelli Y, Lacasa D (2002) Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 143: 930-940.
12. Dukes M, Miller D, Wakeling AE, Waterton JC (1992) Antiuterotrophic effects of a pure antioestrogen, ICI 182, 780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 135: 239-247.
13. Early Breast Cancer Trialists Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467.
14. Espie M (1994) Megestrol acetate in advanced breast carcinoma. Oncology 51(Suppl 1): 8-12.
15. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG (1990) Inhibition of estrogen receptor-DNA binding by the ‘pure’ antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87: 6883-6887.
16. Filardo EJ (2002) Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80: 231-238.
17. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63: 2434-2439.
18. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167-1177.
19. Hu XF, Veroni M, De Luise M, Wakeling A, Sutherland R, Watts CK, Zalcberg JR (1993) Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780. Int J Cancer 55: 873-876.
20. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S (2002) Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29: 175-192.
21. Johnston SR (2001) Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 7: 4376s-4387s
22. Johnston SR, Head J, Pancholi S, Detre S, Martin L, Smith IE, Dowsett M (2003) Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9: 524S-532S
23. Jonat W, Maass H (1978) Some comments on the necessity of receptor determination in human breast cancer. Cancer Res 38: 4305-4306.
24. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
25. Katzenellenbogen BS, Katzenellenbogen JA (2000) Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2: 335-344.
26. Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA (2000) Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 55: 163-193.
27. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930.
28. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P (1987) Functional domains of the human estrogen receptor. Cell 51: 941-951.
29. Lee YT, Markland FS (1978) Steroid receptors study in breast carcinoma. Med Pediatr Oncol 5: 153-166.
30. Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4: 46-56.
31. Lykkesfeldt AE, Larsen SS, Briand P (1995) Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529-534.
32. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164, 384 and ICI 182, 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587-1595.
33. MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196.
34. McClelland RA, Gee JM, Francis AB, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI (1996a) Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 32A: 413-416.
35. McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI (1996b) Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 41: 31-41.
36. Nicholson RI, Gee JM, Francis AB, Manning DL, Wakeling AE, Katzenellenbogen BS (1995a) Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growthindependent (K3) human breast cancer cells. Endocr Relat Cancer 2: 115-121.
37. Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS (1995b) Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann NY Acad Sci 761: 148-163.
38. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505-3512.
39. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746-750.
40. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE (1994) The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34: 89-95.
41. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9: 1-13.
42. Paszko Z, Padzik K, Dabska M, Pienkowska F (1978) Estrogen receptor in human breast cancer in relation to tumor morphology and endocrine therapy. Tumori 64: 495-506.
43. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL (1999) Randomized trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54: 117-122.
44. Philips A, Chalbos D, Rochefort H (1993) Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1. activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268: 14103-14108.
45. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M (2001) Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5- pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61: 6739- 6746.
46. Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55: 371-374.
47. Tsai MJ, O’Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486.
48. Wakeling AE (1995) Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 49: 1545-1549.
49. Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7: 17-28.
50. Wakeling AE, Bowler J (1987) Steroidal pure antioestrogens. J Endocrinol 112: R7-R10.
51. Wakeling AE, Bowler J (1988) Novel antioestrogens without partial agonist activity. J Steroid Biochem 31: 645-653.
52. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873.
53. Wardley AM (2002) Fulvestrant: a review of its development, pre-clinical and clinical data. Int J Clin Pract 56: 305-309.
54. White R, Parker MG (1998) Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 5: 1-14.